State Key Laboratory of Oncology in South China, Guangzhou, 510060, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
State Key Laboratory of Oncology in South China, Guangzhou, 510060, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Eur J Surg Oncol. 2020 Oct;46(10 Pt B):e3-e6. doi: 10.1016/j.ejso.2020.06.004. Epub 2020 Jun 14.
Gastrointestinal cancer is one of the most common cancers in China. Due to the late detection for most patients, the overall prognosis of gastrointestinal cancer is still poor. At present, the treatment of gastrointestinal cancer includes surgery, radiotherapy, ablation, chemotherapy, targeting, immunity and other treatment methods. Therefore, with the continuous improvement of individualized treatment, we hope to improve the effect of gastrointestinal cancer treatment by promoting the research progress of anti-tumor drugs. Although China's research in the field of gastrointestinal cancer drug treatment has only begun relatively recently, there has been rapid development in our progress. An increasing number of research studies led by Chinese researchers have attracted international attention, influencing clinical practices all over the world and adding to China's contribution to the global field of medicine. This article reviews China's main contributions in the clinical research of gastrointestinal cancer drugs in the past two years.
胃肠道癌症是中国最常见的癌症之一。由于大多数患者发现较晚,胃肠道癌症的总体预后仍然较差。目前,胃肠道癌症的治疗包括手术、放疗、消融、化疗、靶向、免疫等治疗方法。因此,随着个体化治疗的不断提高,我们希望通过促进抗肿瘤药物的研究进展来提高胃肠道癌症治疗的效果。尽管中国在胃肠道癌症药物治疗领域的研究相对较晚才开始,但我们的进展非常迅速。越来越多的由中国研究人员领导的研究引起了国际关注,影响了全球各地的临床实践,并为中国对全球医学领域的贡献增添了力量。本文回顾了过去两年中国在胃肠道癌症药物临床研究方面的主要贡献。